Preparation of epirubicin-loaded poly(butyl cyanoacrylate) colloidal particles by polymerization in a mixed organic-aqueous solvent system

Colloids and Surfaces A: Physicochemical and Engineering Aspects

Volumn 431, Issue , 2013, Pages 27-33

  Bedzhova, Zorka ^a   Yordanov, Georgi ^a  

^a UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Acetone; Emulsion polymerization; Epirubicin; Mixed solvent system; Nanoparticles; Poly(butyl cyanoacrylate)

Indexed keywords

ACETONE; ADHESIVES; DEXTRAN; DISPERSIONS; EMULSION POLYMERIZATION; MOLECULAR MASS; SOLVENTS;

COLLOIDAL DRUG CARRIERS; DRUG-LOADING EFFICIENCY; EPIRUBICIN; MIXED-SOLVENT SYSTEMS; MOLECULAR MASS DISTRIBUTIONS; ORGANIC-AQUEOUS SOLVENTS; PHOSPHATE-BUFFERED SALINES; POLY(BUTYL CYANOACRYLATE);

NANOPARTICLES;

ACETONE; CITRIC ACID; CYANOACRYLATE DERIVATIVE; DEXTRAN 40; EPIRUBICIN; NANOPARTICLE; ORGANIC SOLVENT; POLOXAMER; POLY(BUTYL CYANOACRYLATE); POLYMER; UNCLASSIFIED DRUG; WATER;

ACIDITY; AQUEOUS SOLUTION; ARTICLE; COLLOID; CONTROLLED STUDY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; EMULSION; MOLECULAR WEIGHT; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; ZETA POTENTIAL;

EID: 84877909863     PISSN: 09277757     EISSN: 18734359     Source Type: Journal    
DOI: 10.1016/j.colsurfa.2013.04.035     Document Type: Article

References (42)

1. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56:185-229.
2. Menna P., Paz O., Chello M., Covino E., Salvatorelli E., Minotti G. Anthracycline cardiotoxicity. Expert Opin. Drug Saf. Supl 2012, 1:S21-S36.
3. Cortés-Funes H., Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc. Toxicol. 2007, 7:56-60.
4. Gewirtz D. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57:727-741.
5. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986, 46:6387-6392.
6. Hashizume H., Baluk P., Morikawa S., McLean J., Thurston G., Roberge S., Jain R., McDonald D. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 2000, 156:1363-1380.
7. Maeda H., Sawa T., Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 2001, 74:47-61.
8. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 2011, 63:131-135.
9. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J. Control. Release 2012, 164:138-144.
10. ® the first FDA-approved nano-drug: lessons learned. J. Control. Release 2012, 160:117-134.
11. Gabizon A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992, 52:891-896.
12. Daruwalla J., Greish K., Malcontenti-Wilson C., Muralidharan V., Iyer A., Maeda H., Christophi1 C. styrene maleic acid-pirarubicin disrupts tumor microcirculation and enhances the permeability of colorectal liver metastases. J. Vasc. Res. 2009, 46:218-228.
13. Wohlfart S., Khalansky A., Bernreuther C., Michaelis M., Cinatl J., Glatzel M., Kreuter J. Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles. Int. J. Pharm. 2011, 415:244.
14. Yordanov G. Advanced strategies for drug delivery in nanomedicine (Chapter 1). Colloid and Interface Chemistry for Nanotechnology 2013, CRC Press, (in press). P. Kralchevsky, R. Miller, F. Ravera (Eds.).
15. Ruenraroengsak P., Cook J., Florence A. Nanosystem drug targeting: facing up to complex realities. J. Controlled Release 2010, 141:265-276.
16. Vauthier C., Dubernet C., Fattal E., Pinto-Alphandary H., Couvreur P. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv. Drug Deliv. Rev. 2003, 55:519-548.
17. Nicolas J., Couvreur P. Synthesis of poly(alkyl cyanoacrylate)-based colloidal nanomedicines Wiley interdisciplinary reviews. Nanomed. Nanobiotechnol. 2009, 1:111-127.
18. Murthy R.S.R., Reddy L.H. Poly(alkyl cyanoacrylate) nanoparticles for delivery of anti-cancer drugs. Nanotechnology for Cancer Therapy 2006, 251-288. CRC Press, Boca Raton (FL, USA). M.M. Amiji (Ed.).
19. Yordanov G. Poly(alkyl cyanoacrylate) nanoparticles as drug carriers: 33 years later. Bulg. J. Chem. 2012, 1:61-73.
20. Yordanov G., Skrobanska R., Evangelatov A. Entrapment of epirubicin in poly(butyl cyanoacrylate) colloidal nanospheres by nanoprecipitation: formulation development and in vitro studies on cancer cell lines. Colloids Surf. B 2012, 92:98-105.
21. Pereverzeva E., Treschalin I., Bodyagin D., Maksimenko O., Kreuter J., Gelperina S. Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats. Toxicol. Lett. 2008, 178:9-19.
22. Ambruosi A., Khalansky A., Yamamoto H., Gelperina S., Begley D., Kreuter J. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J. Drug Target. 2006, 14:97-105.
23. Gulyaev A., Gelperina S., Skidan I., Antropov A., Kivman G., Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 1999, 16:1564-1569.
24. Maksimenko O., Pavlov E., Toushov E., Molin A., Stukalov Y., Prudskova T., Feldman V., Kreuter J., Gelperina S. Radiation sterilisation of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles. Int. J. Pharm. 2008, 356:325-332.
25. Blagoeva P., Balansky R., Mircheva T., Simeonova M. Diminished genotoxicity of mitomycin C and farmorubicin included in polybutylcyanoacrylate nanoparticles. Mutat. Res. 1992, 268:77-82.
26. Page-Clisson M.-E., Pinto-Alphandary H., Ourevitch M., Andremont A., Couvreur P. Development of ciprofloxacin-loaded nanoparticles: physicochemical study of the drug carrier. J. Control. Release 1998, 56:23-32.
27. Yordanov G., Bedzhova Z., Dushkin C. Preparation and physicochemical characterization of novel chlorambucil-loaded nanoparticles of poly(butylcyanoacrylate). Colloid. Polym. Sci. 2010, 288:893-899.
28. Mouridsen H., Alfthan C., Bastholt L., Bergh J., Dalmark M., Eksborg S., et al. Current status of epirubicin (Farmorubicin) in the treatment of solid tumours. Acta Oncol. 1990, 29:257-285.
29. Plosker G., Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993, 45:788-856.
30. Coukell A., Faulds D. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer. Drugs 1997, 53:453-482.
31. Beijnen J., Wiese G., Underberg W. Aspects of the chemical stability of doxorubicin and seven other anthracydines in acidic solution. Pharmaceutisch Weekblad 1985, 7:109-116.
32. Scherer D., Robinson J., Kreuter J. Influence of enzymes on the stability of polybutylcyanoacrylate nanoparticles. Int. J. Pharm. 1994, 101:165-168.
33. Behan N., Birkinshaw C., Clarke N. Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerisation and particle formation. Biomaterials 2001, 22:1335-1344.
34. Douglas S.J., Illum L., Davis S.S., Kreuter J. Particle size distribution of poly(butyl-2-cyanoacrylate) nanoparticles: I. Influence of physicochemical factors. J. Colloid Interface Sci. 1984, 101:149-158.
35. Douglas S.J., Illum L., Davis S.S., Particle Size Size distribution of poly(butyl-2-cyanoacrylate) nanoparticles: II. Influence of stabilizers. J. Colloid Interface Sci. 1985, 103:154-163.
36. Aggarwal P., Hall J., McLeland C., Dobrovolskaia M., McNeil S. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 2009, 61:428-437.
37. Yordanov G. Influence of the preparation method on the physicochemical properties of econazole-loaded poly(butyl cyanoacrylate) colloidal nanoparticles. Colloids Surf., A 2012, 413:260-265.
38. Arias J.L., Gallardo V., Linares-Molinero F., Delgado A.V. Preparation and characterization of carbonyl iron/poly(butylcyanoacrylate) core/shell nanoparticles. J. Colloid Interface Sci. 2006, 299:599-607.
39. Yang S.C., Ge H.X., Hu Y., Jiang X.Q., Yang C.Z. Doxorubicin-loaded poly(butylcyanoacrylate) nanoparticles produced by emulsifier-free emulsion polymerization. J. Appl. Polym. Sci. 2000, 78:517-526.
40. Poupaerta J., Couvreur P. A computationally derived structural model of doxorubicin interacting with oligomeric polyalkylcyanoacrylate in nanoparticles. J. Control. Release 2003, 92:19-26.
41. Yordanov G., Evangelatov A., Skrobanska R. Epirubicin loaded to pre-polymerized poly(butyl cyanoacrylate) nanoparticles: preparation and in vitro evaluation in human lung adenocarcinoma cells. Colloids Surf. B 2013, 107:115-123.
42. Vansnick L., Couvreur P., Christiaens-Leyh D., Roland M. Molecular weights of free and drug-loaded nanoparticles. Pharm. Res. 1985, 2:36-41.